| Identification | Back Directory | [Name]
Unii-580bnq45EO | [CAS]
1403357-81-2 | [Synonyms]
ACT001(DMAMCL)
Unii-580bnq45EO
CAS:1403357-81-2
ACT001(UNII-580BNQ45EO)
Azuleno[4,5-b]furan-2(3H)-one, 3-[(dimethylamino)methyl]-3a,4,5,7,8,9,9a,9b-octahydro-9-hydroxy-6,9-dimethyl-, (3R,3aS,9R,9aS,9bS)- | [Molecular Formula]
C17H27NO3 | [MOL File]
1403357-81-2.mol | [Molecular Weight]
293.4 |
| Hazard Information | Back Directory | [Description]
Dimethylamino-micheliolide (DMAMCL) is a prodrug form of the sesquiterpene lactone micheliolide (Item No. 25402).1 It inhibits migration and invasion of, and vascular formation by, U-118 MG glioma cells when used at a concentration of 10 μM. DMAMCL enhances cell death induced by the DNA-cross-linking agent cisplatin (Item No. 13119) in U-118 MG cells. In vivo, DMAMCL (200 mg/kg) reduces tumor volume and slows the tumor growth rate in a U-118 MG mouse xenograft model when administered in combination with cisplatin. It also prevents proteinuria and renal failure in a db/db mouse model of diabetic nephropathy.2WARNING This product is not for human or veterinary use. | [References]
[1] XIAONAN XI. ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma[J]. Cell Death & Disease, 2019, 106 1. DOI: 10.1038/s41419-019-1986-2
[2] WENTING LIU . Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice[J]. Pharmacological research, 2019, 150: Article 104506. DOI: 10.1016/j.phrs.2019.104506 |
|
|